We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
- Authors
Gupta, Arjun; Hay, Annette E; Crump, Michael; Djurfeldt, Marina S; Zhu, Liting; Cheung, Matthew C; Shepherd, Lois E; Chen, Bingshu E; Booth, Christopher M
- Abstract
Background: When cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact (""contact days") can help contextualize expected time use with each treatment. We assessed contact days in a completed randomized clinical trial. Patients and Methods: We conducted a secondary analysis of the CCTG LY.12 RCT that evaluated 2-3 cycles of gemcitabine, dexamethasone, and cisplatin (GDP) vs. dexamethasone, cytarabine, and cisplatin (DHAP) in 619 patients with relapsed/refractory lymphoma prior to stem cell transplant. Primary analyses reported similar response rates and survival. We calculated patient-level "contact days" by analyzing trial forms. The study period was from assignment to progression or transplant. Days without healthcare contact were considered "home days". We compared measures of contact days across arms. Results: The study period was longer in the GDP arm (median 50, vs. 47 days, P =.007). Contact days were comparable in both arms (median 18 vs 19, P = 0.79), but home days were higher in the GDP arm (median 33 vs 28, P <.001). The proportion of contact days was lower in the GDP arm (34%, vs. 38%, P =.009). The GDP arm experienced more contact days related to planned outpatient chemotherapy (median, 10 vs. 8 days), but the DHAP arm experienced many more inpatient contact days (median, 11 vs. 0 days). Conclusions: Measures of time use, such as contact days, can be extracted from RCTs. In LY.12, despite comparable oncologic outcomes, GDP was associated with fewer contact days. Such information can guide decision-making for patients with hematological cancers, who already face significant healthcare contact. When cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact ("contact days") can help contextualize expected time use with each treatment. This secondary analysis of the CCTG LY.12 trial analyzed trial forms to assess days with and without health care contact.
- Subjects
STEM cell transplantation; THERAPEUTIC use of antineoplastic agents; DISEASE progression; TIME; DEXAMETHASONE; CANCER chemotherapy; GEMCITABINE; DISEASE relapse; TREATMENT effectiveness; CISPLATIN; DESCRIPTIVE statistics; DECISION making; PATIENT-professional relations; LYMPHOMAS; CYTARABINE; SECONDARY analysis; OUTPATIENT services in hospitals
- Publication
Oncologist, 2023, Vol 28, Issue 9, p799
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad128